Authors	Doris Hillemann;Sabine Rusch-Gerdes;Elvira Richter									Year	2009	
Title	Feasibility of the GenoType MTBDRsI assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens											
LOCATION AN	ID DESIG	3N										
Country	DE				Study design	Study design Not stated						
Clinical setting		Laboratory			Other (specify)	Amika	Amikacin and capreomycin tested together as AM-CM					
Was rapid test run outside of a lab? Not stated						Study blinded?	No	No				
Total samples included in analysis (= screened - withdrawls) 64						Sample type	Pulmo	Pulmonary				
Number after screening by exclusion and inclusion criteria						Other (specify)						
Unit of analysi	nit of analysis not stated					Prior testing by	Prior testing by microscopy for triage?					
						Type of microso	copy used		Yes-Zie	hl-Neelsen		
						Smear type			Concer	ntrated (processed)		
TEST AND RE	FERENC	E TEST										
Rapid test		GenoType MTBDRsI VS.				Reference test	Reference test Solid & Liquid Culture					
Other (specify)]	MTBDRsI Assay					Solid culture details					
Other (specify)	er (specify)				Liquid culture o	Liquid culture details MGIT 960						
Pre-treatment processing of sample? NALC-NaOH						Other (specify)						
						Total No. cultur	es	64				
						Contaminated of	cultures	1				
PARTICIPANT DETAILS						DRUG RESISTA	DRUG RESISTANCE TESTED WITH LINKS TO SENSITIVITY 2 X 2 TABLE					
Study recruitm	nent		Consecutive			Amikacin	No	#	Ofloxacin	Yes	[#]	
Other (specify)]					Moxifloxacin	No	#	Quinolones	No	#	
Participant age	•		notstated			Isoniazid	No	#	Rifampicin	No		
Participant HIV	/ status		not stated			Capreomycin	No	#	Other	No	=	
Previous TB his	story?		Not stated			Ethambutol	Yes	#		Amikacin and capre	eomy	
			No. TB history	Total (incl. TB	history)	Kanamycin	No		(specify)			
Participant outcomes evaluated? Not stated						Were indeterminate results reported for test for drug resistance detection			Yes			